CureVac (CVAC) Competitors $5.46 +0.01 (+0.18%) Closing price 04:00 PM EasternExtended Trading$5.46 0.00 (0.00%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. CRSP, ADMA, PCVX, RYTM, CYTK, KRYS, AKRO, ZLAB, PTCT, and RAREShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Zai Lab (ZLAB), PTC Therapeutics (PTCT), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Its Competitors CRISPR Therapeutics ADMA Biologics Vaxcyte Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Akero Therapeutics Zai Lab PTC Therapeutics Ultragenyx Pharmaceutical CRISPR Therapeutics (NASDAQ:CRSP) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability. Do analysts rate CRSP or CVAC? CRISPR Therapeutics presently has a consensus price target of $71.75, suggesting a potential upside of 26.32%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 25.15%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more volatility & risk, CRSP or CVAC? CRISPR Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CRSP or CVAC? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor CRSP or CVAC? In the previous week, CRISPR Therapeutics had 9 more articles in the media than CureVac. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 3 mentions for CureVac. CureVac's average media sentiment score of 1.06 beat CRISPR Therapeutics' score of 0.60 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRSP or CVAC more profitable? CureVac has a net margin of 35.44% compared to CRISPR Therapeutics' net margin of -1,023.64%. CureVac's return on equity of 30.89% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,023.64% -20.08% -17.13% CureVac 35.44%30.89%25.54% Which has higher valuation & earnings, CRSP or CVAC? CureVac has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M131.47-$366.25M-$4.52-12.57CureVac$579.18M2.11$175.50M$0.925.93 SummaryCureVac beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio5.937.5819.7619.92Price / Sales2.11292.00430.8999.65Price / Cash6.2442.8637.4658.16Price / Book1.637.638.045.49Net Income$175.50M-$55.05M$3.18B$250.27M7 Day Performance1.20%8.54%3.72%4.78%1 Month Performance34.15%5.38%3.72%7.20%1 Year Performance66.97%2.35%29.92%17.27% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.6868 of 5 stars$5.46+0.2%$6.83+25.2%+75.2%$1.22B$579.18M5.93880Positive NewsCRSPCRISPR Therapeutics3.2751 of 5 stars$51.19-1.9%$71.75+40.2%+6.2%$4.51B$37.31M0.00460Analyst ForecastOptions VolumeADMAADMA Biologics3.9697 of 5 stars$17.88-2.2%$27.67+54.7%+53.9%$4.36B$426.45M32.64530Positive NewsPCVXVaxcyte1.8897 of 5 stars$32.00-3.8%$136.50+326.6%-55.2%$4.29BN/A0.00160News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.2062 of 5 stars$66.39+0.9%$78.07+17.6%+100.6%$4.18B$130.13M0.00140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics3.9936 of 5 stars$33.36-3.8%$70.92+112.6%-33.4%$4.14B$18.47M0.00250KRYSKrystal Biotech4.5767 of 5 stars$139.74-2.3%$211.13+51.1%-22.6%$4.13B$290.52M31.87210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionAKROAkero Therapeutics3.427 of 5 stars$51.52-0.5%$82.50+60.1%+116.7%$4.13BN/A0.0030Insider TradeZLABZai Lab3.2781 of 5 stars$35.48-2.5%$54.28+53.0%+99.9%$4.04B$398.99M0.001,869Gap UpPTCTPTC Therapeutics4.3467 of 5 stars$47.98-2.2%$65.00+35.5%+55.9%$3.89B$806.78M6.771,410RAREUltragenyx Pharmaceutical3.9586 of 5 stars$39.61-0.8%$87.00+119.6%-26.9%$3.77B$560.23M0.001,294Trending NewsAnalyst ForecastTrading Halted Related Companies and Tools Related Companies CRSP Competitors ADMA Competitors PCVX Competitors RYTM Competitors CYTK Competitors KRYS Competitors AKRO Competitors ZLAB Competitors PTCT Competitors RARE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
